实用临床医学
實用臨床醫學
실용림상의학
Practical Clinical Medicine
2014年
12期
4-6
,共3页
李希丽%任爽%诸葛金科%刘功伟%庄芊茹%陈晶美%李必迅
李希麗%任爽%諸葛金科%劉功偉%莊芊茹%陳晶美%李必迅
리희려%임상%제갈금과%류공위%장천여%진정미%리필신
肺癌%非小细胞肺癌%小细胞肺癌%空腹血糖
肺癌%非小細胞肺癌%小細胞肺癌%空腹血糖
폐암%비소세포폐암%소세포폐암%공복혈당
lung cancer%non-small cell lung cancer%small cell lung cancer%fasting blood glucose
目的：探讨肺癌患者与空腹血糖（FBG）的关系。方法选择入院前未经治疗、无糖尿病史的肺癌患者560例为研究组，根据细胞学类型分为2个亚组：小细胞肺癌组（70例）及非小细胞肺癌组（490例）。非小细胞肺癌组再根据病理分型分为鳞癌组（156例）、腺癌组（292例）和腺鳞癌组（42例）。另选取同期住院治疗的无糖尿病史的非恶性肿瘤患者500例为对照组。所有患者晨起采集空腹静脉血2 mL，采用葡萄糖氧化酶法进行FBG测定。对各组的FBG进行比较。结果除鳞癌组外，研究组及各亚组患者FBG明显高于对照组（均P＜0.05）。研究组、小细胞癌组、非小细胞肺癌组、腺癌组及腺鳞癌组6.1 mmol·L-1＜FBG≤7.0 mmol·L-1发生率高于对照组（P＜0.05）；研究组、小细胞肺癌组患者3.9 mmol·L-1≤FBG≤6.1 mmol·L-1发生率低于对照组（P＜0.05）。研究组各亚组患者的FBG比较差异均无统计学意义（均P＞0.05）。结论肺癌患者特别是小细胞癌、腺癌及腺鳞癌患者较容易发生FBG升高，且考虑与肺癌本身有关。
目的：探討肺癌患者與空腹血糖（FBG）的關繫。方法選擇入院前未經治療、無糖尿病史的肺癌患者560例為研究組，根據細胞學類型分為2箇亞組：小細胞肺癌組（70例）及非小細胞肺癌組（490例）。非小細胞肺癌組再根據病理分型分為鱗癌組（156例）、腺癌組（292例）和腺鱗癌組（42例）。另選取同期住院治療的無糖尿病史的非噁性腫瘤患者500例為對照組。所有患者晨起採集空腹靜脈血2 mL，採用葡萄糖氧化酶法進行FBG測定。對各組的FBG進行比較。結果除鱗癌組外，研究組及各亞組患者FBG明顯高于對照組（均P＜0.05）。研究組、小細胞癌組、非小細胞肺癌組、腺癌組及腺鱗癌組6.1 mmol·L-1＜FBG≤7.0 mmol·L-1髮生率高于對照組（P＜0.05）；研究組、小細胞肺癌組患者3.9 mmol·L-1≤FBG≤6.1 mmol·L-1髮生率低于對照組（P＜0.05）。研究組各亞組患者的FBG比較差異均無統計學意義（均P＞0.05）。結論肺癌患者特彆是小細胞癌、腺癌及腺鱗癌患者較容易髮生FBG升高，且攷慮與肺癌本身有關。
목적：탐토폐암환자여공복혈당（FBG）적관계。방법선택입원전미경치료、무당뇨병사적폐암환자560례위연구조，근거세포학류형분위2개아조：소세포폐암조（70례）급비소세포폐암조（490례）。비소세포폐암조재근거병리분형분위린암조（156례）、선암조（292례）화선린암조（42례）。령선취동기주원치료적무당뇨병사적비악성종류환자500례위대조조。소유환자신기채집공복정맥혈2 mL，채용포도당양화매법진행FBG측정。대각조적FBG진행비교。결과제린암조외，연구조급각아조환자FBG명현고우대조조（균P＜0.05）。연구조、소세포암조、비소세포폐암조、선암조급선린암조6.1 mmol·L-1＜FBG≤7.0 mmol·L-1발생솔고우대조조（P＜0.05）；연구조、소세포폐암조환자3.9 mmol·L-1≤FBG≤6.1 mmol·L-1발생솔저우대조조（P＜0.05）。연구조각아조환자적FBG비교차이균무통계학의의（균P＞0.05）。결론폐암환자특별시소세포암、선암급선린암환자교용역발생FBG승고，차고필여폐암본신유관。
Objective To explore the relationship between lung cancer and fasting blood glucose (FBG). Methods A total of 560 patients with lung cancer who received no treatment before admission to hospital and had no history of diabetes were selected as the case group. These patients were further divided into two groups:small cell lung cancer group (n=70) and non-small cell lung cancer group (n=490). Moreover, these patients with non-small cell lung cancer were further divided into three groups:squamous carcinoma group(n=156), adenocarcinoma group(n=292) and adenosquamous carcinoma group (n=42).In addition, 500 non-malignant tumor patients with a history of diabetes who received treatment during the same period were enrolled as the control group. Fasting venous blood samples (2 mL) were collected and FBG levels were determined by glucose oxidase method. Results Compared with control group, the levels of FBG and the incidence of 6.1 mmol·L-1<FBG≤7.0 mmol·L-1 significantly increased in small cell lung cancer group, adenocarcinoma group and adenosquamous carcinoma group, but the incidence of 3.9 mmol·L-1≤FBG≤6.1 mmol·L-1 obviously decreased in small cell lung cancer group(all P<0.05). There were no significant differences in FBG levels between small cell lung cancer group and non-small cell lung cancer group, as well as among squamous carcinoma group, adenocarcinoma group and adenosquamous carcinoma group (P>0.05). Conclusion FBG levels often increase in patients with lung cancer, especially in patients with small cell lung cancer, adenocarcinoma or adenosquamous carcinoma. There is a correlation between FBG levels and lung cancer.
